Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma - Journal of Translational Medicine
- news.google.com language
- 2025-06-05 20:13 event
- 2 weeks ago schedule